Wolfe Research analyst Mike Polark upgraded iRhythm to Peer Perform from Underperform without a price target. The analyst sees a more balanced risk/reward following the stock’s underperformance.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IRTC:
- New Research Confirms that Zio® by iRhythm Provides High Value From a Health Economic Perspective
- iRhythm® Technologies Comments on the Final Medicare Physician Fee Schedule Released by the Centers for Medicare and Medicaid Services for Calendar Year 2023
- iRhythm price target lowered to $166 from $175 at Oppenheimer
- iRhythm® Technologies Comments on the Announcement of the Medicare Physician Fee Schedule Final Rule Released by the Centers for Medicare and Medicaid Services for Calendar Year 2023
- iRhythm comments on announcement of MPFS Final Rule for calendar year 2023